Editorial Office, Mediastinum. Email: med@amegroups.com
On June 26, 2021, we received the good news from Elsevier that Mediastinum has been accepted for inclusion in Scopus.
Mediastinum (ISSN 2522-6711) is an open access and peer-reviewed medical journal publishing papers on all benign, malignant, and metastatic diseases related to or affecting the mediastinum, such as thymic epithelial tumors, lymphomas, germ cell or neurogenic tumors and metastasis diseases including lung cancer and esophageal cancer. Led by Dr. Wentao Fang as the Editor-in-Chief, Mediastinum is further supported by a strong lineup of over 80 experts worldwide as the Editorial Board members. Mediastinum provides a professional platform for colleagues around the world to share advanced research results, up-to-date knowledge and unique experiences for better understanding and management of mediastinal diseases.
We can’t achieve this without the continuous support and contributions of the journal’s editorial board members, guest editors, authors, reviewers and readers. We here would like to extend our sincere gratitude to all the contributors. We will keep striving to publish high-quality articles and make Mediastinum to the forefront.